Kayode Emmanuel Ogunniyi

Kayode Emmanuel Ogunniyi

Auto-generated profile, based on publicly available information

Kayode Emmanuel Ogunniyi

Richmond University Medical Center/Mount Sinai, Staten Island, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2025 in ESC Heart Failure
Verified
Journal Article
Open access
TAToluwalase Awoyemi
Toluwalase Awoyemi
OTOluwaremilekun Zeth Tolu-Akinnawo
Oluwaremilekun Zeth Tolu-Akinnawo
AMArun Mahtani
Arun Mahtani
IPInderbir Padda
Inderbir Padda
KOKayode Emmanuel Ogunniyi
Kayode Emmanuel Ogunniyi
MFMina Fattah
Mina Fattah
Cardiovascular disease is a leading cause of maternal morbidity and mortality. As cardio-obstetric care evolves, digital health technologies including telehealth, wearable devices and remote monitoring are playing an increasingly critical role. These innovations have the potential to enhance cardiovascular screening, risk assessment and disease management across the perinatal continuum. This article explores the role of digital health technologies in advancing cardio-obstetrics care. It focuses on the impact of telehealth, wearable sensors and emerging digital tools on improving maternal cardiovascular outcomes and reducing disparities in care delivery. A narrative review approach was used to synthesize existing literature and clinical insights related to telecardiology, wearable monitoring and digital innovations. Emphasis was placed on applications in pregnancy and post-partum care, as well as on evaluating implementation challenges and equity concerns. Digital health tools improve access to care and facilitate early diagnosis of cardiovascular conditions. Telehealth increases care continuity and patient satisfaction, especially in underserved populations. Wearable devices equipped with photoplethysmography and electrocardiogram sensors enable intermittent, non-invasive monitoring, aiding early detection of arrhythmias and hypertensive disorders. Furthermore, novel technologies such as digital twins, natural language processing and virtual reality show potential to personalize care and support medical education. Despite these advancements, key barriers persist, including data privacy concerns, unequal access to technology and algorithmic bias. Digital health technologies are transforming cardio-obstetrics care by enabling proactive management and expanding access. However, for these tools to deliver equitable benefits, targeted efforts are needed to address privacy, infrastructure and literacy challenges. Future efforts should focus on integrating digital health into routine maternal care, promoting digital literacy, ensuring equitable technology access and improving interoperability with electronic health records. Additionally, ongoing evaluation through clinical trials in high-risk pregnancies and ethical safeguards to mitigate algorithmic bias will be essential to ensure safe, scalable and inclusive implementation of these innovations in maternal cardiovascular care.

30 August 2025 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
KOKayode Ogunniyi
Kayode Ogunniyi
Chukwuemeka Christian AghasiliChukwuemeka Christian Aghasili
Chukwuemeka Christian Aghasili
OAOlumide Akinmoju
Olumide Akinmoju
VOVictor Olamiposi Olaiya
Victor Olamiposi Olaiya
OAOluwamisimi Abib
Oluwamisimi Abib
FRFrancesco Rotatori
Francesco Rotatori

1 January 2025 in International Journal of Hepatology
Verified
Journal Article
Open access
KOKayode E. Ogunniyi
Kayode E. Ogunniyi
HAHabib Olatunji Alagbo
Habib Olatunji Alagbo
OTOluwaremilekun Zeth Tolu-Akinnawo
Oluwaremilekun Zeth Tolu-Akinnawo
SISelimat Ibrahim
Selimat Ibrahim
OAOluwaseun Dorcas Adeleke
Oluwaseun Dorcas Adeleke
TAToluwalase Awoyemi
Toluwalase Awoyemi
Background and Aims: Ischemic stroke remains a leading cause of preventable cardiovascular mortality worldwide, with emerging evidence suggesting an association between liver cirrhosis and both stroke occurrence and severity. However, the specific impact of cirrhosis on stroke‐related mortality remains incompletely understood. Elucidating this relationship is crucial for improving risk stratification and early recognition of high‐risk individuals. Methods : We conducted a retrospective cohort study comparing ischemic stroke patients with cirrhosis to those without, using the National Inpatient Sample database for 2021. Univariate and multivariate logistic regression analyses were performed to compare various outcomes. Results: A total of 536,199 discharges for ischemic stroke were included, among which 4464 had a documented history of liver cirrhosis. Discharges with cirrhosis were predominantly male (58.2%) with a mean age of 67 years, which was 2.17 years younger than those without cirrhosis. In‐hospital mortality was 7% (95% CI: 5.5%–8.99%) among discharges with cirrhosis versus 4.2% (95% CI: 4.0%–4.33%) in those without.. After adjusting for cofounders in multivariate logistic regression, it was revealed that cirrhosis is associated with 69% higher mortality risk in stroke discharges (OR = 1.69, 95% CI: 1.27–2.25, p < 0.001). Conclusions: Our study identifies liver cirrhosis as an independent risk factor for mortality among patients hospitalized with ischemic stroke. These findings underscore the necessity of incorporating proactive management strategies for liver cirrhosis into stroke care and prevention protocols, potentially improving outcomes in this high‐risk population.

23 May 2026 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
KOKayode E. Ogunniyi
Kayode E. Ogunniyi
TDTrie Arni Djunadi
Trie Arni Djunadi
SASamuel Abiola Ayedun
Samuel Abiola Ayedun
VOVictor Onyenokwe
Victor Onyenokwe
OOOghenevwede Anderson Okuma
Oghenevwede Anderson Okuma
AGAndrew Greek
Andrew Greek

28 September 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
HNHenry Eziefule Nwankwo
Henry Eziefule Nwankwo
KOKayode E Ogunniyi
Kayode E Ogunniyi
COChisom Okezue
Chisom Okezue
DDDivine Dele
Divine Dele
YAYusuff Adebisi
Yusuff Adebisi
TRThomas A Rocco
Thomas A Rocco
Aims: Heart-focused anxiety (HFA) is a disease-specific construct characterized by fear of cardiac sensations, attentional hypervigilance, and behavioural avoidance of exertion. It is conceptually related to, but empirically separable from, generalized anxiety, but is rarely screened for in cardiac rehabilitation (CR). No prior systematic review has synthesized evidence on its prevalence, predictors, or CR implications. Methods and results: PubMed, CINAHL, PsycINFO, and the Cochrane Library were searched following PRISMA 2020 guidelines. Eligible studies measured HFA using the Cardiac Anxiety Questionnaire (CAQ) or Herzangstfragebogen (HAF-17) in adults with confirmed cardiovascular disease (CVD). Cross-sectional, cohort, validation, and intervention designs were eligible. Quality was appraised using NIH NHLBI Study Quality Assessment Tools and Cochrane Rob-2. Narrative synthesis was performed. This systematic review was prospectively registered on PROSPERO (CRD420261394690). Twenty-six studies, with a combined enrolled sample of 9628 patients across eight countries were included. Clinically elevated HFA ranged from 15% to 49% depending on the population, timing of assessment, and CAQ cut-off used. HFA was associated with depressive symptoms, illness perception, and impaired quality of life, and findings suggests a bidirectional relationship with physical inactivity. HFA independently predicted major adverse cardiac events and mortality post-MI in two prospective cohorts (HR range 1.30–1.59), with avoidance as the primary driver. Standard CR, specialized psychocardiological CR, device therapy, and early mobilization were associated with reductions in HFA. Conclusion: HFA is prevalent across CVD diagnoses and was independently prognostic for adverse cardiovascular outcomes in two prospective cohorts. Several rehabilitation and psychological interventions were associated with HFA reductions, though the evidence remains largely observational. Routine CAQ screening at CR intake and targeted cognitive behavioural interventions for patients with elevated HFA warrant evaluation in future prospective studies.

10 July 2026 in ASIDE Endocrinology
Verified
Journal Article
Open access
PDF file
ZAZubair Ahmed
Zubair Ahmed
FNFalak Naz
Falak Naz
KOKayode Ogunniyi
Kayode Ogunniyi
KCKanchan Chaudhary
Kanchan Chaudhary
SAShaista Ali
Shaista Ali
LALaksh Kumar Ahuja
Laksh Kumar Ahuja
BackgroundHeart failure frequently coexists with cardiometabolic conditions commonly associated with metabolic syndrome. Characterizing long-term mortality patterns involving these co-reported conditions may help identify populations with a disproportionate burden. MethodsWe performed a national serial cross‑sectional analysis using the CDC WONDER Multiple Cause of Death database to examine mortality among U.S. adults aged ≥25 years from 1999 to 2023. Eligible deaths included those with at least one heart failure ICD‑10 code and at least one metabolic syndrome–related ICD–10 code recorded anywhere on the death record. Age‑adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were assessed using Joinpoint regression and stratified by sex, race/ethnicity, U.S. Census region, urbanization (1999–2020), and state. ResultsA total of 1,562,715 deaths co‑reporting heart failure and metabolic syndrome–related conditions were identified. The overall AAMR increased from 24.7 in 1999 to 38.3 in 2023. After declining from 2005 to 2012, mortality increased beginning in the mid-2010s, with a pronounced acceleration during 2018–2021 and a modest decline thereafter. AAMRs were higher among men, non-Hispanic Black and American Indian or Alaska Native populations, residents of the Midwest (with comparatively elevated rates also observed in the West and South), and individuals in nonmetropolitan areas. ConclusionsMortality involving deaths co‑reporting heart failure and metabolic syndrome–related conditions increased substantially after 2012, with marked disparities by sex, race/ethnicity, geography, and urbanization, underscoring the need for equity‑focused cardiometabolic prevention strategies.